Exosomes Are Being Sold Faster Than They Are Being Studied

Three different things wearing one word

The word 'exosome' is currently doing duty for three entirely separate propositions, and the marketing depends on you not noticing the seams.

There is the research field: extracellular vesicles as mediators of cell-to-cell signalling, which is a legitimate, well-funded and genuinely exciting area of cell biology with real potential in medicine.

There is the topical product: serums, ampoules and masks containing something described as exosomes, sold over the counter or as a post-procedure application.

And there is the injected grey market: clinics offering exosome injections for skin, hair and joints, which is a regulatory matter rather than a cosmetic one.

Those three have wildly different evidence bases and wildly different risk profiles, and a product page that opens with the cell biology and closes with a purchase button is inviting you to transfer confidence from the first to the second. This is a summary of where each one actually stands.

What an exosome is, briefly and correctly

Exosomes are small extracellular vesicles — membrane-bound packets, broadly 30 to 150 nanometres in diameter, released by cells and taken up by other cells. They carry proteins, lipids and nucleic acids including microRNA, and they function as a signalling mechanism: one cell packaging instructions and dispatching them to another.

That is a real and important biological system, and the interest in it is not hype. If you could reliably deliver a defined cargo of signalling molecules to a specific cell population, you would have something powerful. Research groups are pursuing exactly that across oncology, wound healing, neurology and regenerative medicine.

None of which establishes that a bottle on a shelf contains functional versions of these vesicles, that they reach living cells when you apply it, or that anything measurable happens if they do. Those are three additional claims, and each needs its own evidence.

What the regulator actually says

The FDA's position is unusually easy to quote, which is convenient given how much marketing copy talks around it.

In its consumer alert on regenerative medicine products, the agency states that exosome products are regulated by the FDA; that as a general matter, exosome products intended to treat diseases or conditions in humans require FDA approval; and then, flatly: 'There are currently no FDA-approved exosome products.'

The same alert notes that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system and not for other uses.

The agency has also warned patients and consumers about unapproved products derived from human cells and tissues marketed for a wide range of conditions, and has reported harms associated with them including infections, blindness and tumour formation. Warning letters to companies marketing exosome products with therapeutic claims have been issued and continue to be.

A distinction worth holding onto: a cosmetic sold with a cosmetic claim sits in a different regulatory category from a product injected with a therapeutic claim. The serum in a shop and the vial in a clinic are not equivalently regulated, and it is the injected end where the FDA's enforcement attention has landed. If a clinic offers to inject anything described as exosomes, that is the situation the alerts are about, and 'it's just a natural product' is not a regulatory status.

The verdict from inside aesthetic medicine

It would be easy to characterise scepticism here as outsiders sniping at a young field. The most damning assessments have come from within it.

In 2025, Aesthetic Plastic Surgery published a systematic review of regenerative aesthetics — the umbrella covering stem cell and exosome therapy, polydeoxyribonucleotide, photobiomodulation and related interventions. The authors, a group of practising aesthetic physicians and surgeons, reviewed 19 studies including 14 randomised controlled trials. Their conclusion: the field lacks the necessary scientific rigour and regulatory compliance to be recognised as a legitimate medical specialty, with a prevalent gap in molecular and clinical evidence, inadequate reporting, unclear mechanisms and an absence of long-term safety data.

The same group published a companion overview review with a title that requires no interpretation: Exosomes Exposed: Overview Systematic Review on Evidence Versus Expectation in Aesthetic and Regenerative Medicine.

When aesthetic plastic surgeons publish that about their own field's most commercially successful new category, in their own specialty journal, the sceptical position is not the fringe one. It is the peer-reviewed one.

The topical problem nobody addresses on the label

Set the regulation aside and consider whether a topical exosome product could work on its own terms. Two obstacles, and the first is close to decisive.

Delivery. An exosome is 30 to 150 nanometres across. The stratum corneum is a formidable barrier that permits passive diffusion of small, appropriately lipophilic molecules — conventionally cited at a few hundred daltons — and a nanoscale lipid vesicle is orders of magnitude outside that. Intact skin does not admit it.

Which is precisely why these products are almost always positioned as post-procedure applications: applied immediately after microneedling, fractional laser or radiofrequency, when the barrier has been deliberately breached and channels exist. That is a coherent delivery rationale, and it is simultaneously an admission — the identical bottle applied to intact skin in a bathroom has no plausible route in. A product sold for both uses is making two claims of very different quality.

Viability. Even granting delivery, are the vesicles in the bottle intact and biologically active? They must survive isolation, formulation, any sterilisation step, shipping, and months at ambient temperature in a warm bathroom. Nothing on a cosmetic label reports this, no standardised potency assay is disclosed to consumers, and 'exosome' on an ingredient list is a description of an input rather than a guarantee about what is in the jar you bought.

It is worth reading these lists rather than the front of the box, and the ingredient decoder will do it. In practice, products like The INKEY List Exosome Hydro-Glow Complex, Medik8 Exo-PDRN Prismatic+ Serum, Dermalogica Phyto Nature E2 and COSRX PDRN Exosome Skinplaning Glaze Mask pair the headline ↗exosome or ↗PDRN claim with a supporting cast of conventional, well-evidenced ingredients — ↗niacinamide, ↗ectoin, hyaluronic acid, centella, ↗peptides. Those are frequently good formulations. The question worth asking is which line on the list is producing the result you notice, and whether the premium attaches to the line with the evidence or the line with the story.

How to evaluate the add-on you are about to be offered

The commonest encounter is not a shelf but a clinic: you are booked for microneedling or laser, and at the appointment an exosome 'boost' is offered for a few hundred more.

Four questions make that decision tractable. What specifically is the product, and how is it regulated here — as a cosmetic, or as something making a therapeutic claim? Is it being applied topically after the procedure, or injected? Those are different propositions and the second is the one the safety alerts concern. What evidence exists for this product, for this indication? Not for exosomes in general, and not for cell biology — for the thing in the vial. And what does it add over the procedure alone, given that microneedling and fractional resurfacing have their own well-documented effects?

That last question is the one the sales material cannot answer, and it has a structural reason: a before-and-after gallery for a combined treatment cannot separate the components. The needling did something documented. The add-on is the untested variable, presented inside a photograph that the tested variable produced. Learning ↗how to read a clinic's before-and-after photographs is worth more here than any ingredient knowledge, and the broader ↗checklist of questions before any cosmetic procedure covers the rest. The derm visit prep tool is a reasonable place to write them down, because these are hard questions to remember when someone is being enthusiastic at you.

And to be fair to the field, since fairness is the point: none of this says exosomes do not work. It says nobody has yet shown that they do, in this format, at this price, for this indication — and that the honest description of the category is promising and unproven. That is a perfectly respectable thing for a technology to be. It is simply not what is being sold, and the gap between those two descriptions is currently being charged for.